Almotriptan in der Routine-Behandlung akuter Migräneattacken: eine Post-Marketing-Studie mit 899 Patienten

Zusammenfassung

In einer Postmarketing-Studie konnten 899 Patientinnen und Patienten mit Migräne bis zu 3 konsekutive Migräneattacken mit Almotriptan (12,5 mg) behandeln. Dokumentiert wurden so 2131 behandelte Migräneattacken. Eine Wirkung nach 2 Stunden, d. h. eine Besserung der Kopfschmerzen von schwer oder mittelschwer auf leichte oder keine Kopfschmerzen wurde bei 84,5% der behandelten Migräneattacken berichtet. Der Prozentsatz der Patienten, die nach 2 Stunden schmerzfrei waren betrug 41,4%. Almotriptan wurde gut vertragen, nur 29 unerwünschte Ereignisse wurden dokumentiert.

Summary

In a postmarkting study 899 patients with migraine could treat up to 3 consecutive migraine attacks with 12,5 mg almotriptan. 2131 treated attacks were documented. Improvement of headache from severe or moderate to mild or no headache after 2 hours was reported in 84.5% of treated migraine attacks. The rate of pain free patients after 2 hours was 41.4%. Almotriptan was well tolerated, only 29 adverse events were reported.

Schlüsselwörter

Migräne - Migräneattacke - Almotriptan

Keywords

Migraine - migraine attack - almotriptan

• Literatur

• 1 Bou J, Domenech T, Puig J, Hereda A, Gras J, Fernandez-Forner D, Beleta J, Palacios JM. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 2000; 410: 33-41.
• 2 Cabarrocas X, Zayas JM, Suris M. on behalf of the Almotriptan Oral Study Group. Equivalent efficacy of oral almotriptan, a new 5-HT1B/D agonist, compared with sumatriptan 100 mg. Headache 1998; 38: 377-8.
• 3 Dahlöf C, Tfelt-Hansen P, Massiou H, Fazekas A. and the Almotriptan Study Group. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 2001; 57: 1811-7.
• 4 Dahlöf CGH, Dodick D, Dowson AJ, Pascual J. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache 2002; 42: 99-113.
• 5 InternationalHeadache Society Clinical Trials Subcommitee Tfelt-Hansen P, Block G, Dahlöf C, Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C, Sandrini G, Steiner T, Winter PBO. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20: 765-86.
• 6 Keam SJ, Goa KL, Figitt DP. Almotriptan. A review of its use in migraine. Drugs 2002; 62: 387-414.
• 7 Mathew NT. Almotriptan increases pain-free status in acute migraine patients treated in placebo-controlled trials (abstract). Cephalalgia 2001; 21: 428.
• 8 Mathew NT. Oral Almotriptan Study Group. A long-term open-label study of oral almotriptan 12.5mg for the treatment of acute migraine. Headache 2002; 42: 32-40.
• 9 Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002; 42: 28-31.
• 10 Pascual J, Falk R, Docekal R, Prusinski A, Jelencsik J, Cabarrocas X, Segarra X, Luria X, Ferrer P. Tolerability and efficacy of almotriptan in long-term treatment of migraine. European Neurology 2001; 45: 206-13.
• 11 Pascual J, Falk RM, Piessens F, Prusinski A, Docekal P, Robert M, Ferrer P, Luria X, Segarra R, Zayas JM. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000; 20: 588-96.
• 12 Spierings E, Gomez-Mancilla B, Grosz D, Rowland C, Whaley F, Jirgens K. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 2001; 58: 944-50.